“Novo Nordisk is deeply concerned that, without aggressive intervention by federal and state regulators and law enforcement, patients will continue to be exposed to the significant risks posed by knockoff ‘semaglutide’ drugs made with illicit or inauthentic foreign active pharmaceutical ingredients,” Novo said.
Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert
